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Abstract 
Infectious diseases caused by viruses, parasites and bacteria are currently the 
second cause of mortality worldwide. One of these parasites is Leishamania spp., 
which is the protozoa responsible for leishmaniasis. Although, considered the ninth 
largest infectious disease burden worldwide, is still one of the most neglected 
tropical disease. Leishmaniasis has three main syndromes, which can range in 
severity from a relatively benign, self-limiting cutaneous form, to a potentially fatal 
systemic illness, known as visceral leishmaniasis. While cutaneous leishmaniasis is 
the most widespread on a global scale, visceral leishmaniasis is the most severe and 
lethal form of the disease. Another important tropical disease is malaria, caused by 
Plasmodium spp. protozoan parasite and transmitted by a female infected Anopheles 
mosquito tropical disease. 
The control of both diseases still relies on chemotherapy, but the armamentarium 
currently used have their use limited due to several adverse effects, elevated cost, 
lack of efficacy, and appearance of resistant parasites. Additionally, there is no 
effective vaccine to fight either leishmaniasis or malaria. For these reasons, the 
search for new therapeutic approaches are urgent. Endoperoxides are known to be 
reductively activated by iron(II)-heme to form carbon centered radicals and reactive 
oxygen species which can generate oxidative stress inside parasites. Both, 
Leishmania and Plasmodium require high levels of iron at critical steps of their life 
cycle, and therefore, these compounds could be promising to the design and 
discovery of new drugs, since this hybrid compounds can act by a dual mechanism 
and thus can be more effective than single drugs. In this thesis it is proposed the 
development of endoperoxide-based hybrid compounds which can generate 
oxidative stress inside the parasite and alkylate biomolecules essential to the parasite 
survival, and at the same time can deliver an , -unsaturated compound able to 
inhibit essential enzymes to the parasite. The synthetic route occurs in two steps. 
First, an aldehyde or ketone is treated with formic acid and hydrogen peroxide to 
give the intermediate gem-dihydroperoxide. Then, trans-cinnamaldehyde and 
Re2O7 are added to complete conversion into 1,2,4,5-tetraoxane. In this study, seven 
novel tetraoxanes were synthesized and fully characterized. In addition, the 
activation in biomimetic conditions was performed using FeBr2, being the reaction 
followed by HPLC. Synthesized compounds were evaluated for their antiparasitic 
activity. 
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Resumo 
 
As doenças infeciosas causadas por vírus, parasitas e bactérias são atualmente a 
segunda maior causa de mortalidade a nível mundial. 
Um desses parasitas é a Leishmania spp., protozoário responsável pela 
leishmaniose. Esta doença é atualmente considerada a nona maior doença infeciosa a 
nível mundial já que afeta cerca de 12 milhões de pessoas em praticamente todos os 
continentes (Europa, África, América e Ásia). Apesar disso, o interesse por parte da 
indústria farmacêutica é diminuto sendo classificada como uma doença negligenciada. 
Encontra-se difundida tanto em áreas tropicais como em áreas subtropicais sendo 
considerada endémica em 98 países, segundo a Organização Mundial de Saúde (OMS). 
Esta doença afeta principalmente as populações mais pobres, em países em vias de 
desenvolvimento e é responsável por cerca de 30 000 mortes por ano, números que têm 
vindo a aumentar a um ritmo alarmante. 
A leishmaniose pode causar um amplo espectro de patologias em humanos, as 
quais podem variar em severidade desde uma forma relativamente benigna da doença, 
porém limitante, designada por leishmaniose cutânea, passando por uma variante que 
consiste num desfiguramento facial, como acontece na leishmaniose mucocutânea, 
podendo mesmo chegar a uma patologia potencialmente fatal, a leishmaniose visceral. 
A leishmaniose cutânea é a forma mais comum da doença, sendo que em cada 1,3 
milhões de casos totais que surgem anualmente, 1 milhão são referentes à leishmaniose 
cutânea e apenas 0,3 milhões são relativos à leishmaniose visceral. Esta última, apesar 
de ser uma forma menos frequente da doença é a mais severa, podendo conduzir à morte 
se não for devidamente tratada. A leishmaniose mucocutânea representa a forma mais 
destrutiva da doença. 
Existem mais de 20 espécies de Leishmania consideradas infeciosas para o ser 
humano, entre elas estão a L. donovani, L. infantum, L. siamensis, L. braziliensis e L. 
guyanensis. A leishmaniose é transmitida 
infetada pelo parasita, que normalmente pertence ao género Lutzomia 
(América Central e do Sul) e do género Phlebotomus Velho 
e Ásia). 
Uma outra doença tropical é a malária cuja infeção é causada por parasitas do 
género Plasmodium spp., transmitidos aos humanos através da picada de um mosquito 
fêmea infetado pertencente ao género Anopheles. 
Existem seis espécies do parasita capazes de infetar humanos, tais como o P. 
falciparum, P. vivax, P. malariae, P. ovale, P. ovale wallikeri e P. knowlesi. De entre 
estas espécies o P. falciparum é a que origina a forma mais perigosa e fatal da malária 
e, em conjunto com o P. vivax são as espécies mais comuns. 
A malária é uma doença tropical que representa um dos problemas públicos mais 
preocupantes, já que, de acordo com a OMS, existem cerca de 212 milhões de novos 
casos por ano que conduzem a aproximadamente 430 000 mortes anuais, sendo que a 
maioria ocorre em África e em crianças com menos de cinco anos de idade. 
Para estas duas doenças tropicais a realidade é a mesma, já que não existem 
vacinas eficientes e o seu controlo encontra-se limitado ao uso de quimioterapia e à 
prevenção. Infelizmente, a quimioterapia atualmente utilizada para ambas as doenças é 
a mesma desde há várias décadas, por isso, o seu uso também se encontra limitado 
devido ao aparecimento de resistências, e ainda devido aos diversos efeitos secundários 
e ao seu elevado custo. Todas estas razões conduzem a uma procura urgente de novos 
agentes terapêuticos. É importante que as novas alternativas terapêuticas, para além de 
eficazes, sejam economicamente acessíveis, uma vez que estas doenças afetam 
principalmente os países em vias de desenvolvimento. 
Neste contexto surgem os endoperóxidos, que são uma família de compostos 
capazes de serem redutivamente ativados pelo ferro (II), levando à formação de espécies 
reativas de oxigénio, radicais centrados no carbono e compostos carbonílicos. Assim, os 
endoperóxidos podem atuar por diferentes mecanismos de ação. Por um lado, estes 
compostos têm a capacidade de aumentar o stress oxidativo dentro do parasita, podem 
ainda alquilar biomoléculas essenciais para a sobrevivência dos parasitas. Por outro lado, 
se se libertar o composto carbonílico , -insaturado, pode reagir como aceitador de 
Michael levando à inibição de enzimas necessárias à sobrevivência dos parasitas. Deste 
modo, estes compostos podem ser utilizados contra qualquer agente infecioso que 
disponha de elevadas concentrações de ferro em pontos críticos do seu ciclo de vida, tal 
como acontece com os parasitas dos géneros Leishmania e Plasmodium. 
Seguindo esta linha de raciocínio, nesta tese é reportada a síntese de uma pequena 
biblioteca de novos compostos 1,2,4,5-tetraoxanos que são capazes de atuar através de 
um mecanismo de dupla ação, uma vez que, após a ativação pelo ferro (II), irá formar-
se uma espécie radicalar, aumentando o stress oxidativo. Ao mesmo tempo, liberta-se 
uma molécula carbonílica , -insaturada, neste caso o trans-cinamaldeído, capaz de 
inibir a tripanotiona redutase (TR) no caso da Leishmania, e a falcipaína no caso do P. 
falciparum. Estas enzimas desempenham papéis cruciais nos parasitas, a TR participa 
na defesa antioxidante do parasita Leishmania, enquanto que a falcipaína é uma das 
enzimas presente no vacúolo digestivo do Plasmodium responsável pela hidrólise da 
hemoglobina. 
Estes 1,2,4,5-tetraoxanos são preparados com recurso a uma síntese em dois 
passos. No primeiro passo, os aldeídos ou cetonas reagem com ácido fórmico e com 
peróxido de hidrogénio dando origem ao intermediário gem-dihidroperóxido. O segundo 
passo usa o óxido de rénio (VII) como catalisador, para formar um complexo com o 
trans-cinamaldeído, que posteriormente é adicionado ao intermediário de modo a 
permitir a conversão no produto final 1,2,4,5-tetraoxano. Deste modo, o trans-
cinamaldeído foi escolhido como segundo reagente por ser um composto , -insaturado, 
podendo ser um potencial inibidor das enzimas TR e falcipaína. 
Assim, conseguiram-se sintetizar e purificar sete novos compostos híbridos (21-
27) baseados na estrutura tetraoxano com rendimentos moderados a bons. Estes 
compostos foram ainda caracterizados utilizando-se técnicas de ressonância magnética 
nuclear, nomeadamente RMN 1H, RMN 13C, COSY, APT, HMQC e HMBC.  
De modo a confirmar a ativação pelo ferro (II) e a consequente libertação do 
composto , -insaturado, os compostos foram estudados em condições biomiméticas na 
presença de brometo de ferro (II), seguindo-se a reação por HPLC. Com estes estudos 
confirmou-se que o trans-cinamaldeído é libertado na presença de brometo ferroso, 
confirmando-se que o ferro (II) consegue ativar eficientemente esta classe de compostos. 
Todos os compostos apresentaram tempos de semi-vida curtos, o que indica que são 
rapidamente ativados pelo ferro (II). Estes estudos foram uma prova de conceito que 
mostraram que o composto carbonílico , -insaturado é rapidamente libertado após a 
ativação dos tetraoxanos pelo ferro (II), sugerindo que estes endoperóxidos poderão ter 
comportamentos semelhantes in vivo. 
A capacidade antiparasitária dos tetraoxanos sintetizados foi avaliada para a 
malária e para a leishmaniose. Relativamente à malária, os compostos demonstraram ser 
moderadamente ativos, revelando melhores valores de inibição na gama do sub- M para 
a estirpe Dd2 do Plasmodium falciparum. A atividade dos compostos foi ainda testada 
para a forma promastigota de Leishmania donovani, porém, devido a problemas de 
solubilidade, nenhum dos compostos revelou atividade. 
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Chapter 1 
 
  
Inducing oxidative stress in parasites
1. State of the Art 
 
1.1 Neglected Tropical Diseases 
 
A group of heterogenous infectious diseases are classified as tropical diseases, 
neglected diseases, diseases of the developing world, and diseases of poverty.1  
For a better understanding of the topic, Heras, et al
principally, in tropical areas, such as malaria, leishmaniasis, Chagas disease, African 
trypanosomiasis and dengue, the second term means that in spite of the high mortality 
and/or morbidity produced by the disease, little scientific attention and resources have been 
dedicated to understanding and curing them.1 
Neglected tropical diseases (NTD) are a group of chronic, disabling and disfiguring 
conditions that can affect more than two billion people worldwide (about one third of the 
total population) and nearly two million deaths per year, mostly in the poorest areas of the 
planet.1 4 
Common characteristics of NTD include high endemicity in rural and impoverished 
urban areas of low-income countries, ability to impair childhood growth, and they are both 
cause and consequence of poverty, profound effect on demography, negative impact in 
cognitive and educational development as well as adverse effects in work productivity.1,5 
Chemotherapy plays a key role in treating, helping to control or eliminate diseases in 
the developing world. Nevertheless, the majority of the drugs used to treat or prevent NTD 
has remained essentially unchanged since the middle of the 20th century, so many of them 
have toxicity issues, poor efficacy or have lost efficacy due to emergence and spread drug 
resistance.1,5 The fact that, sometimes, the patients do not complete the course of treatment 
it is because of the cost, availability, invasive route of administration, and long treatment 
duration, increasing the chances of development of drug resistance. In addition, there are 
no effective vaccines for most of NTD. So, due to the wide diffusion of these diseases, the 
small number of effective drugs and the frequent emergence of resistance, the drug 
discovery in this therapeutic area is a very urgent and challenging task. Unfortunately, big 
pharmaceutical companies do not invest in drug discovery programs because of low 
financial returns. However, over the past few years, this gap has started to reduce 
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considerably as several non-profit organizations have intervened heavily and efficaciously 
to sustains this research.2,6 
Two of the most prevalent pathogenic diseases in many countries around the world 
are, undoubtedly, leishmaniasis and malaria, characterized by a very high morbidity, 
lethality as well as a widespread diffusion across the planet. 2,5 7 
 
1.2   Leishmaniasis 
 
Leishmaniasis is a vector-borne disease caused by a heterogeneous group of 
protozoan parasites of the Kinetoplastidae order, Trypanosomatidae family, and 
Leishmania genus.1,8 12 There are more than 20 species of Leishmania which are infectious 
to humans, such as L. donovani, L. infantum, L. siamensis, L. braziliensis, and L. 
guyanensis. Leishmania protozoan species are a hemoflagellate group responsible for 
human leishmaniasis, which has several other species has reservoir, such as rodents, 
canines, equines, marsupials and other in the wild animal population. Due to the ability of 
this infectious agent to circulate among both humans and animals, leishmaniasis can be 
considered as an important zoonosis.13 16  
This infectious disease is transmitted by the bite of an infected female sandfly of the 
genera Lutzomyia in the New World (central and south America) and Phlebotomus in the 
Old World (Africa, Asia, Europe).12,13,15,17 This vectors are smaller than mosquitoes, so the 
prevention is more difficult, since they can cross standard mosquito nets.8,18 
Leishmaniasis affects about 12 million people on all continents, being widespread in 
tropical and subtropical areas and found in 98 countries.9,19 22  It is regarded as a major 
public health problem, causing significant morbidity and mortality with near 1.3 million 
new cases per year, and about 350 million people are globally threatened. Furthermore, the 
number of cases is increasing globally at an alarming rate.13,16,22 24 Is reported that although, 
leishmaniasis represents the ninth largest infectious disease burden worldwide, is still 
considered one of the most NTD.7,22,25 
The disease affects largely the poorest of the poor people, mainly in developing 
countries, because its associated with malnutrition, population displacement, poor housing, 
weak immune system and lack of resources.13,24,26 The increase of the incidence of this 
disease can also be associated to environmental changes, such as deforestation, building of 
dams, irrigation schemes, global warming, and urban development.13,16,23  
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The main reasons for this blowout in endemic and non-endemic regions, and the 
primary hurdles in the elimination of leishmaniasis are related to a lack of effective control 
measures for both parasite and its vector, the poor knowledge about the disease itself, and 
lack of effective health policies. Furthermore, this infections can last for decades leading 
to an economic, social, and political consequences.5,27,28 
The geographic distribution of different Leishmania species can induce distinct types 
of the disease in each region as well as its severity. It is estimated that between 0.2 to 0.4 
and 0.7 to 1.3 million people are newly infected every year with visceral leishmaniasis (VL) 
and cutaneous leishmaniasis (CL), respectively, but only a small fraction of them will 
develop the disease and about 20 000 to 30 000 will eventually die from leishmaniasis.22,29 
VL is highly endemic in the Indian subcontinent and in East Africa. According to the 
World Health Organization (WHO), in 2015, more than 90% of new cases occurred mostly 
in seven countries: Brazil, Ethiopia, India, Kenya, Somalia, South Sudan and Sudan.11,27 
VL emerge essentially in tropical and subtropical areas but, due to global warming the 
disease is now spreading to temperate regions such as Brazil and Argentina, suggesting that 
these climates do not restrict the adaption of vectors in these regions.30  
CL is endemic in more than 70 countries worldwide, and 95% of cases occur in the 
Americas, the Mediterranean basin, the Middle East and Central Asia (Figure 1.1).23,31,32 
Similar to the previous case, more than two thirds of new CL cases occur mainly in six 
countries: Afghanistan, Algeria, Brazil, Colombia, Islamic Republic of Iran and Syrian 
Arab Republic.11,24,27 Although CL is widespread on a global scale, it is often quite focal in 
some regions, due to the specific habitat requirements of the sandfly vector and its hosts.16 
Leishmaniasis causes a wide spectrum of pathologies in humans, which can range in 
severity from a relatively benign and self-limiting cutaneous form nominated as CL, to 
facial disfigurements which can occur in mucocutaneous leishmaniasis (ML) or to 
potentially fatal VL, also known as kala-azar.6,24,33 Despite the differences between the 
pathologies of those manifestations, there are some factors that can influence the clinical 
presentation and prognosis, such as the duration of infection, the host immune response and 
also depends on the infecting species and, consequently, the endemic region.8,9,34 
The incubation of this pathology can range from a few days to months, which can 
lead to misdiagnosis of the skin lesions.16 When an infected vector bites the host, the 
infection of CL begins in this precise spot, where a papule appear. It can then enlarge to a 
nodule and ulcerates with a period of time of 1-3 months.24,34 Lesions are generally painless 
unless secondary infection occurs, and the disease is frequently self-cured within months 
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to years, depending on the Leishmania species, leaving behind disfiguring, lifelong 
cutaneous scars.16,17,24,35  
 
 
ML, characterized by infection in the mucous membranes of mouth, nose or pharynx, 
is mainly caused by L. braziliensis, L. panamensis and L. guyanensis and usually appears 
1 to 5 years after CL has healed.16,19,23,36 
The infection starts at the site of inoculation with an erythema and ulcerations at the 
nasal mucosa, then the disease can spread to the nasal septum causing perforations and even 
destructive inflammatory lesions. When lesions progress to the pharynx and larynx, it can 
obstruct theses organs and lead to remarkable disfigurement and sometimes death.19,23,24,37 
In ML, spontaneous self-healing does not occur, and the treatment is difficult. Moreover, 
it can lead to bacterial coinfections which could be potentially fatal.23 
VL is the most severe form of leishmaniasis and it can lead to death if untreated, since 
its lesions affects internal organs like spleen, liver, and lymph nodes. The disease as an 
incubation period that can range from 2 to 6 months and it can present an acute, subacute 
or chronic evolution. However, many infected patients can remain asymptomatic.19,30,34,38,39 
The main manifestations of the disease are prolonged fever, cough, weight loss, weakness, 
diarrhea or dysentery, and abdominal swelling. Some patients can also present progressive 
Figure 1.1  Worldwide status of CL, in 2013. Adapted from WHO   24/06/2017 
http://www.who.int/Leishmaniasis/burden/Leishmaniasis_Burden_distribution_VL_CL_2013.pdf 
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anemia, edema, bleeding episodes, and even splenomegaly, hepatomegaly, and 
pancytopenia.19,30,38 40 
In the latent cases, which patients remain undiagnosed, the symptoms can appear 
several years after infection. In these cases, they become immunocompromised and their 
skin become darker, defining the origin of the disease synonym kala-azar, which means 
black fever in the Hindi language.38 Moreover, patients with no symptoms and no overt 
signs of VL can function as reservoirs in endemic regions.30 
Another variant of the main pathologies is post-kala-azar dermal leishmaniasis 
(PKDL), which is caused by L. donovani and can emerge months to years in patients who 
have been treated against VL.24,30,38,39 The infection begins around the mouth, nodules can 
increase in size and become generalized all over the body or even evolve into ulcers, in 
which PKDL patients become reservoirs of Leishmania parasites. In more severe cases, the 
infection can lead to blindness. 24,30,38 
 
1.2.1 Life cycle 
 
The life cycle develops in two different organisms, an insect vector (sandfly) and a 
mammalian host. Leishmania parasites have dual-morphological forms: amastigotes, which 
are intracellular and non-motile, and promastigotes, flagellated motile and extracellular 
(Figure 1.2). Promastigotes undergoes through several morphological states of 
differentiation until become amastigote, which is the infectious form of the parasite.6,8,18 
Besides the fact that iron acquisition has been poorly described, it is known that the 
low iron environment is a potent trigger for the differentiation of promastigote into infective 
amastigote.10,41 Within parasitophorous vacuoles of macrophages, the harsh acidic 
environment would destroy most microorganisms.7 However, the intracellular stages of 
Leishmania have developed an adaptive mechanism that allow them to survive. One of the 
adaptions is the acquisition of essential nutrients, such as iron, which can be obtained as 
inorganic iron or from heme.7,10 Promastigotes can activate the expression of ferrous iron 
transporters, which increase the iron uptake and involves reactive oxygen species (ROS) 
production.41 Due to the redox potential of Leishmania, iron can be toxic in high amounts, 
so the acquisition systems must be tightly regulated.7 
 
Inducing oxidative stress in parasites
 
Figure 1.2  Leishmania life cycle. Adapted from18 
 
The life cycle starts when a sandfly feeds on a mammalian host, releasing metacyclic 
promastigotes and several salivary components. Upon inoculation into the vertebrate host, 
promastigotes are phagocytosed by one of the several cells types, such as macrophage, 
where they lose the flagella becoming amastigotes.18,34 This form replicate within the 
macrophage, which then suffer rupture, releasing the parasites, allowing the reinfection of 
new cells.8,18 
The cycle is completed when the amastigote form of Leishmania is ingested by 
another sandfly. Once in the midgut of the vector, the organism is converted into 
noninfective procyclic promastigotes and then into non-dividing metacyclic promastigotes, 
which are ready to infect another mammal.8,18 
 
1.2.2 Trypanothione reductase 
 
Trypanothione was discovered, in 1985, as a result of studies on an apparently 
unusual glutathione reductase (GR) activity in the African trypanosome, Tryoanosoma 
brucei brucei. It is a conjugate of glutathione and the polyamine spermidine, which is a 
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component of the structure of trypanothione disulfide (TS2), rationalizing the actions of 
several antileishmanial drugs.42,43 
Trypanothione reductase (TR) is a member of the NADPH-dependent flavoprotein 
oxidoreductase, central to the unique thiol-redox cycling system, which is common to 
trypanosomiasis and leishmaniasis, and is structurally and mechanistically related to GR of 
mammals. The glutathione system found in human host, is responsible for the maintenance 
of an intracellular reducing environment important for the reduction of disulfides, 
detoxification of peroxides, and the synthesis of DNA precursors. The trypanothione 
system is thought to protect the parasite against damage by oxidants, xenobiotics and toxic 
heavy metals.44,45 The enzymatic regeneration of the thiol pool in Leishmania parasites is 
dependent on TR. This enzyme has a vital physiological role, particularly in  highly 
oxidative environment within the host cells, generated during the antiparasitic defense 
response.43,45 
In mammals, a glutathione (GSH)-based system act as a first defense against 
oxidative stress, leading to glutathione disulfide (GSSG), 1 (Figure 1.3). The regeneration 
of protective GSH, 2, from GSSG is catalyzed by GR.  
 
Figure 1.3  GR-catalyzed reduction of glutathione disulfide 1 to two thiol glutathione 2. Adapted from42 
 
In Leishmania parasites occur an analogous system, where dithiol trypanothione 
(T(SH)2), 4, differs from GSSG by the presence of a spermidine cross link between the two 
glycyl carboxyl groups. Additionally, the enzyme TR can reduce TS2, 3, to T(SH)2 in a 
manner analogous to GR (Figure 1.4).43 
Unlike human hosts, Leishmania parasites contain TR instead of analogous enzyme 
GR to process their cognate substrates trypanothione and glutathione, respectively. Parasite 
TR does not process GSSG and host does not reduce TS2. Therefore, the design of selective 
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inhibitors of TR could be important in the development of drugs against leishmanial 
infections, due to the mutually exclusive recognition and rejection of cognate substrates 
between host and parasite.45 
 
Figure 1.4  TR-catalyzed reduction of trypanothione disulfide 3 to dithiol trypanothione 4. Adapted from42 
1.2.3 Current Treatments for leishmaniasis 
 
To date, there are no effective vaccines and there is no single effective treatment for 
all Leishmania species and syndromes. The control of leishmaniasis primarily relies on 
chemotherapy, however current treatment modalities usually do not result in parasitological 
cure.39,46 Most of the available therapeutic arsenal for leishmaniasis (Figure 1.5) has several 
limitations related to adverse effects, elevated cost, need of hospitalization during all 
treatment, lack of efficacy, and development of drug resistance. Moreover, is important to 
notice that a response to a drug can vary from an endemic region to another.39 
Within the armamentarium against leishmaniasis are pentavalent antimonial 
compounds (Sbv), which have been the standard first-line treatment recommended for CL, 
ML and VL, for several decades.17,38,39 This type of compounds include drugs such as 
sodium stibogluconate 5 or meglumine antimoniate 6, however, due to their poor oral 
absorption, these compounds have to be administered intravenously, intramuscularly or 
directly into the lesions.17,38 In addition, these are expensive therapies, adding the fact the 
need for hospitalization due to cardiac and toxicity problems, increasing the limitation of 
using this therapy for leishmaniasis.17,32,47  
It was suggested that Sbv drugs act with a dual mode of action. When in  contact with 
macrophages, Sbv can stimulate them to kill the intracellular parasites, and  inside parasites 
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they can undergo with a biological reduction to a more active trivalent antimonite, SbIII,  
acting as a produg, and kill directly the parasite inside the phagolysosome by inhibiting 
trypanothione reductase.35,39,48 
Amphotericin B (AmB) 7, is another drug used against leishmaniasis. Is a polyene 
antibiotic isolated from Streptomyces nodosus, and have typically been used as the second 
line of treatment for VL and ML since 1960.17,38,39  
The mechanism of action is not fully understood, however it is assumed that AmB 
can interfere with cell membrane of Leishmania parasite, changing its permeability and 
leaking of intracellular components.39,49 Despite the excellent cure rates, high safety and 
efficacy, AmB has many adverse effects, which include difficult administration, 
nephrotoxicity, hypokalemia, and myocarditis, so this treatment also needs hospitalization 
and close monitoring, thus the cost of this therapy can escalate.17,38  
 
Paromomycin 8, is an aminoglycoside antibiotic isolated from Streptomyces 
krestomuceticus, which is used as a second line drug to circumvent the problems of SbV 
resistance.35,38,39,50 The main adverse effects are fever, reversible ototoxicity, rise in hepatic 
transaminases, and pain at injection site, which may pose difficulty in its adoption in a 
control program of a developing country. However this event does not lead to the 
discontinuation of therapy.6,38,39 Besides all these disadvantages, this compound continues 
to be used mainly because of its affordability.38 
The mechanism of action is through interference with protein synthesis in the 
ribosome of the target organism.6,39,50 
 
Miltefosine 9 belongs to the class of alkylphosphocholine drugs, which are 
phosphocholine esters of aliphatic long-chain alcohols. Originally developed as an 
anticancer drug, this compound is the first and only agent used by oral administration for 
all types of leishmaniasis. This was a major breakthrough, since it does not require 
hospitalization and it can offer domiciliary treatment, which increases the adhesion for this 
treatment.31,39,51 53 
Miltefosine revealed strong possibility of an apoptosis-like mode of cell death in L. 
donovani promastigotes and amastigotes, however the mechanism of action is not fully 
understood.33,47,52,54 Moreover, it can produce ROS, inhibition of cytochrome C oxidase 
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and cell death by necrosis which can be explained through the disturbance on the lipid 
membranes.6,39,47,51 
Miltefosine has lower toxicity, however has some limitations, such has teratogenicity 
effects, therefore the use during the pregnancy is strictly contraindicated. 6,24,39,46,50,51  
 
  
Figure 1.5  Armamentarium used for the treatment of leishmaniasis 
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Sitamaquine 10 is an 8-aminoquinoline, and is the second oral drug for leishmaniasis 
treatment.50 As a lipophilic weak base, it can be accumulated inside Leishmania 
promastigotes, namely into acidic compartments, allowing their alkalization.50,55 
Sitamaquine causes some adverse effects such as vomiting, abdominal pains, headache, 
methemoglobinemia, and renal adverse effects.49,55 
Pentamidine 11 is a synthetic derivative from amidine, and is used in individuals 
intolerant to antimonial treatment, or in cases of resistance.17,35,50 It has been used since 
1980 for the treatment of VL, CL and ML, however, it is no longer used for VL due to its 
serious toxicities.38,49 Other side effects include, pain, nauseas, vomiting, myalgia, 
headache, hypotension, syncope, transient hyperglycemia and hypoglycemia.17,39,49 The 
mechanism of action is the inhibition of active transport system and DNA-mitochondrial 
complex.39 
 
 
1.3   Malaria 
 
Malaria is caused by infection with parasites of the genus Plasmodium, and is 
transmitted to humans through the bite of infected female mosquitoes of the genus 
Anopheles.56,57 There are six main strains of human Plasmodium  falciparum, malariae, 
vivax, ovale, ovale wallikeri and knowlesi-, and among these P. vivax and P. falciparum 
are the most common forms, but P. falciparum is the most mortal worldwide.58,59 
Malaria is a tropical disease that represent one of the most important public health 
problems when it concerns to morbidity and mortality for residents and travelers to endemic 
regions. According to the WHO about 212 million cases occurred globally in 2015, leading 
to 429 000 deaths, most of which in children aged under 5 years in Africa. In fact, babies, 
children under the age of 5 years old, and pregnant women are known to be more 
susceptible to malaria.60 64  
The epidemiology of malaria varies geographically, since it depends on the local, 
intensity of transmission or endemicity class. For instance, while Plasmodium falciparum 
is mostly widespread in tropical Africa, the remaining five strains of Plasmodium infections 
are less common and geographically restricted. On the other hand, most of the vectors 
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which transmit the parasite has a broad geographic distribution, being more prevalent in 
Africa.62,65 67 Within endemic countries, malaria represents a heavy burden on the poorest 
and most vulnerable communities, leading to these low-income countries to have highest 
risks associated with malaria, and least access to effective services for prevention, diagnosis 
and treatment.68 
 
 
Figure 1.6  Countries considered endemic for malaria in 2000 and 2016. Adapted from 60  
 
Between 2000 and 2015, there was a substantial progress in fighting this disease, 
which can be proved with the latest estimates from WHO, in which malaria incidence was 
reduced by 41% and malaria mortality rates by 61%. Moreover, at the beginning of 2016 
malaria was considered to be endemic in 91 countries and territories, down from 108 in the 
year 2000, as can be seen in Figure 1.6.60,69 This decrease in the global burden of malaria 
can be explained by the scaling up of measures acquired to strengthening prevention, such 
as the use of insecticide-treated bednets, indoor residual spraying, seasonal malaria 
chemoprevention, rapid malaria diagnosis, and treatment with artemisinin combination 
therapy.62,69 
Despite the remarkable progress towards malaria elimination, the disease continues 
60 
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1.3.1 Life cycle 
 
Malaria parasites exhibits a complex life cycle (Figure 1.7) involving two different 
organisms: a female Anopheles mosquito, the vector, and a vertebrate human host.57,58,62  
The cycle starts with a bite of an infected female mosquito (1), transferring the 
Plasmodium sporozoites to the host during its blood meal (2). These infectious forms of 
the parasite enter the bloodstream and go to the liver, where they invade hepatocytes and 
mature into schizonts. During the liver stage (3), parasite reproduces asexually until several 
thousand of merozoites are produced, which are then released into the bloodstream.57,58,62,70 
In some strains of Plasmodium, such as P. vivax and P. ovale, some liver parasites 
remain quiescent in a so-called dormant forms or hypnozoites, which can relapses months 
or years after the initial infection.58,62 
 
 
Figure 1.7  Plasmodium life cycle 
(1) Anopheles mosquito bite (2) Injected sporozoites (3) Liver stage (4) Erythrocytic stage (5) Formation of 
gametocytes. Adapted from71 
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The erythrocytic stage (4), occurs when the merozoites released from liver invade 
erythrocytic cells. There, Plasmodium parasites undergo through another asexual 
replication producing mature blood schizonts. Once more, erythrocyte lysis can occur, 
releasing differentiated merozoites able to invade new red blood cells, restarting the 
erythrocytic cycle. In this stage, some parasites can differentiate into sexual forms: male 
and female gametocytes (5).58,62 When another mosquito takes a blood meal from an 
infected human, malaria gametocytes are transmitted to the mosquito vector, in which these 
immature gametes undergo maturation, gamete fusion in the insect midgut, producing a 
zygote which develops into a ookinete throughout sexual recombination and meiosis. This 
motile ookinete can transverse the gut wall, and transform into an oocyst, where thousands 
of new sporozoites are produced.57,58,62 
When sporozoites are released from oocyst and migrate to the mosquito salivary 
glands, they are injected in a new human host by the insect bite, restarting the cycle.58,62 
The pathogenesis is caused by the asexual blood stages, so the first symptoms start 
7-10 days after the initial mosquito bite, while the liver phase is asymptomatic.58,65,70 
If the treatment is ineffective, poor-quality or delayed, the parasite burden continuous 
to increase and the patient may evolve to severe malaria, which is potentially lethal.62,72 
 
1.3.2 Falcipain 
 
In P. falciparum, the degradation of the host hemoglobin in a specialized cellular 
organelle called digestive vacuole, is required for sustaining metabolic needs of rapidly 
growth. This degradation is due to a group of proteolytic enzymes called falcipains 
(FP).73,74 
Falcipains are the best characterized cysteine proteases of the malaria parasite, a 
family that include four falcipains: facipain-1 (FP1), falcipain-2 (FP2, also known as 
falcipain-A), falcipain- -B), and falcipain-3 (FP3).73 
All falcipains share a hemoglobinase capacity that appears to be most relevant for 
FP-2, FP- -3. Hemoglobin degradation has proven to be essential for parasite 
survival, therefore, falcipain inhibitors, in particular FP-2 and FP-3 inhibitors, can block 
chemotherapy.75,76 
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1.3.3 Current treatment for malaria 
 
There is no effective vaccine for malaria, and there is still no single drug that can act 
against all Plasmodium strains or all the manifestations of the disease. In addition, 
uncomplicated malaria and severe malaria have distinct treatments. While in 
uncomplicated malaria the first choice is an oral treatment with high efficacy and a low 
adverse-effect profile, for severe malaria a rapid treatment is required. Parental 
administration of an artemisinin derivative is the first choice, because it can rapidly clear 
the parasites from blood, and is also suitable for patients in coma.77 
Malaria prevention and treatment currently relies in chemotherapy and vector control. 
This last one can be achieved by creating a barrier between human host and the mosquitoes, 
interrupting the life cycle of the parasite. Despite resistance and adverse effects, the use of 
antimalarial drugs remain a cornerstone for malaria control.78,79 
 
1.3.3.1. Quinolines 
 
Quinolines constitute a large group of compounds that are active against malaria 
parasites (Figure 1.8). Most drugs from this group, namely quinines, 4-aminoqunolines and 
arylaminoalcohols, are active in cle, but 8-
aminoquinolines target the hepatic stages as well.78 
 
Quinine 12 is a cinchona alkaloid, extracted from the cinchona tree, which was the 
first successful chemical compound used to the treatment of an infectious disease, which 
remains an important antimalarial drug for almost 400 years.80 It has a rapid schizonticidal 
action against intra-erythrocytic malaria parasites, gametocytocidal for Plasmodium vivax 
and Plasmodim malariae, but not for Plasmodium falciparum. It also has analgesic 
properties, but not antipyretic. Unfortunately, its antimalarial mechanism of action is still 
unknown.80 
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Quinine present several side effects, such as tinnitus, hypoglycemia, headache, 
nausea and slight impairment of hearing, which is usually concentration dependent and 
reversible. More severe manifestations comprise vertigo, vomiting, abdominal pain, 
diarrhea, marked auditory loss, and visual symptoms that can lead to loss of vision. Less 
frequent but more severe adverse effects include skin eruptions, asthma, thrombocytopenia, 
hepatic injury and psychosis. Moreover, intramuscular administration of quinine is painful 
and may cause sterile abscesses, which lead to difficult acceptation for patients.80 
 
Primaquine 13 is an 8-aminoquinoline active against the liver and sexual blood stages 
of Plasmodium and has been widely used since 1950s.81 Its major advantage is preventing 
relapses, since it is also active against dormant forms of P. vivax (hypnozoites). However, 
this compound is known for being toxic and poorly tolerated.82,83 
 
Chloroquine 14 is a 4-aminoquinoline effective against the asexual forms in blood 
stage for all types of Plasmodium and highly effective, easily administered, well tolerated 
and inexpensive84 87 The undesirable side effects are ocular toxicity, dry mouth, fatigue, 
and loss of appetite and weight. When therapeutic or high doses are administered too 
rapidly by parental route, it induce acute toxicity, which include several cardiovascular 
effects.85,87 
 
The mechanism of action has not been fully elucidated. However, the most explored 
and accepted theory is that chloroquine interferes with the detoxification of hemozoin. 
During the digestion of hemoglobin, the protein moiety is degraded into peptides and heme 
group, which is toxic to the parasite, so it is transformed in an inert crystalline polymer 
named hemozoin. Chloroquine can accumulate inside the digestive vacuole, bind to 
hematin, a heme dimmer, preventing its incorporation into the hemozoin crystal. The  
detoxification process is compromised and the parasite dies.84,88 
 
Amodiaquine 15 is another 4-aminoquinoline, with an aromatic structure instead of 
the aliphatic side chain of chloroquine. This compound is effective against low-level of 
chloroquine resistance parasites, but not against highly levels. Biotransformation of this 
compound leads to the formation of p-aminophenol moiety into a quinonimine, which is 
responsible for severe hepatotoxicity and life-threatening agranulocytosis.82,89  
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Mefloquine 16, an arylaminoalcohol, was first synthesized in the 1970s. It presents a 
simplified structure of quinine, but better tolerated and more active against most of the 
Plasmodium strains which are resistant to chloroquine. However, problems of resistance 
and toxicity, including anxiety, insomnia, depression, hallucinations, acute psychosis, and 
panic attacks, have limited it use in malaria treatment.82,90 
This compound is a lipophilic drug, characteristic that can facilitate its delivery inside 
 and uninfected 
erythrocytes. This feature contribute to the long half-life of mefloquine, as it may provide 
a reservoir of the drug inside the parasite.90 
The mechanism of action of arylaminoalcohols interfere with the heme digestion, but 
it seems to be different than 4-aminoquinolines. However, it is still not known exactly.82,90 
 
Figure 1.8  Quinolines used for the treatment of malaria 
 
1.3.3.2 Endoperoxides 
Artemisinin 17 is a sesquiterpene lactone isolated from traditional Chinese herb 
Artemisia annua L. in 1972 and its structure was elucidated in 1979 (Figure 1.9). This plant 
has been used in traditional Chinese medicine as a drug for chills and fevers for more than 
2000 years.91,92 
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Figure 1.9  Chemical structure of artemisinin and its derivatives 
17 R: =O; 17a: R: OH; 17b R: OMe; 17c: R: OEt; 17d: R: OC(O)CH2CO2Na 
 
The key pharmacophore of this natural product is the 1,2,4-trioxane group, 
particularly the endoperoxide bridge, which confers the antimalarial activity. Artemisinin 
is only active on blood-stage of parasite life cycle.92,93 
Heme or iron (II), present in high levels inside the parasite, is responsible for the 
opening of the peroxide bridge of the trioxane in artemisinin (Scheme 1.1), leading to the 
formation of ROS or carbon centered radicals.92 94 
 
 
Scheme 1.1  Iron (II)-mediated activation of artemisinin 17. Adapted from95 
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In the first route, the primary oxygen radical can rearrange by a -scission process, 
leading to the formation of carbon centered radicals. While, in the second route, the second 
radical formed suffers a 1,5-H shift between the oxygen radical and a hydrogen from the 
C4 atom, leading to the formation of a carbon centered radical, which can react with 
proteins. These carbon-centered radicals are capable of alkylating parasite biomolecules, 
.88,92,93,95 
Artemisinin therapeutic effect is limited by its low solubility on both oil and water, 
consequently, was reduced to give dihydroartemisinin 17a, which can lead to the 
preparation of a series of semisynthetic analogues, which include artemether 17b, arteether 
17c, and artesunate 17d (Figure 1.9).82,93 
Both artemether 17b and arteether 17c compounds present activity in low single-
nanomolar range against chloroquine-resistant Plasmodium. Artesunate 17d has the 
advantage of being water-soluble becoming possible intravenous administration for the 
treatment of advanced cases of P. falciparum. Dihydroartemisinin 17a is used for the 
treatment of uncomplicated malaria. Moreover, all artemisinin derivatives go through an 
extensive first-pass metabolism and rapid biotransformation to give 
dihydroartemisinin17a, the major active metabolite of artemisinin.93,94 
Artemisinin derivatives still represent the first-choice treatment for malaria due to its 
unique endoperoxide structure, however the complex structure makes it difficult and not 
economically feasible to be chemically synthesized. WHO recommends the use of 
artemisinin in combination with other antimalarial drugs to delay development of 
resistance. Unfortunately, this solution may remain a problem once a large population, 
mostly in Africa, does not have access or financial resources to receive treatment.96 
 
Figure 1.10- Chemical structure of 18 - 1,2,4-Trioxolane; 19- 1,2,4,5-Tetraoxane 
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To overcome the problems of the availability of artemisinin, a new class of synthetic 
peroxides was developed. Among them, trioxolanes 18, and tetraoxanes 19, revealed to be 
potent antimalarial compounds (Figure 1.10).93,95,97 
Vennerstrom et al have described a first class of synthetic endoperoxides, 1,2,4-
trioxolanes 18, however, they had poor water solubility and were chemical unstable.93,98 
Since endoperoxide is the critical pharmacophoric group for antimalarial activity, the 
second stage of Vennerstrom research, was to synthesized molecules with two 
endoperoxide bridges, dispiro 1,2,4,5-tetraoxanes 19, with antimalarial activity and readily 
synthesized in one step.93,95,97,99 
As artemisinin, 1,2,4,5-tetraoxanes are a class of cyclic peroxides, that can be 
activated by iron or heme inside the parasite (Scheme 1.2), leading to the formation of oxy 
radicals that rearrange into carbon-centered radicals. This last compound decomposes into 
two fairly toxic molecules for the parasite, supporting the hypothesis of a dual mechanism 
of action.100 102 
One of these toxic molecules is the carbon-centered radical, which not only is highly 
reactive, leading to alkylation of biomolecules essential for the parasite survival, but also 
contributes to increase the oxidative stress. The other molecule is an , -unsaturated 
carbonyl, which has an electrophilic character, being susceptible to be attacked by 
nucleophiles such as proteins containing active cysteine residues. Therefore, this type of 
compounds are promising inhibitors of both enzymes: TR for Leishmania and falcipain for 
malaria.100 
 
Scheme 1.2  Iron (II)-mediated activation of tetraoxanes derivatives. Adapted from100 
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A key feature of hybrid drugs is the presence of different mechanisms of action, 
against either a single target or different targets, an interesting method to avoid 
monotherapies that increase the emergence of new-drug resistance in parasites.100,103 
Hybrid drugs are defined as chemical entities that combine at least two 
pharmacophores through covalent bond or through a linker. Thus, this linker should be as 
simple as possible, once these compounds are bigger than her parent drugs, and often more 
lipophilic. Recent approaches combines the hybrid and prodrug concepts, in which the 
selective activation of one pharmacophore triggers the release of the second one at the site 
of action.100 
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1.4    
 
Leishmaniasis and malaria, which are caused by Leishmania spp. and Plasmodium 
spp., respectively, are two of the most lethal tropical diseases. Besides the fact both diseases 
entail much concern there are no effective vaccines, so the current armamentarium is 
limited to chemotherapy. Unfortunately, these chemotherapies have their used limited due 
to several adverse effects, elevated cost and emergence of resistant strains. For these 
reasons, the search for new therapeutic approaches is urgent. 
Endoperoxides are known to be reductively activated by iron(II)-heme to form 
carbon-centered radicals, reactive oxygen species and carbonyl species which can generate 
oxidative stress in the parasite. Both, Leishmania and Plasmodium are infectious agents 
that require high levels of iron at critical steps of their life cycle, therefore this kind of 
compounds could be promising to the design and discovery of new drugs. 
1,2,4,5-Tetraoxanes, which have the key factor of possessing an endoperoxide 
bridge, have shown higher stability and potent antimalarial activity. 
Following this concept, the aim of this thesis is to report the synthesis of a small 
library of new compounds containing a 1,2,4,5-tetraoxanes scaffold (Figure 1.11) to 
selectively deliver an electrophile capable of reacting with essential enzymes of both 
parasites, trypanothione reductase for leishmaniasis and falcipain for malaria. 
 
Figure 1.11  Tetraoxanes specific designed for the aim of this work.  
These hybrid compounds can be activated by iron inside parasites, acting through two 
distinct mechanisms of action, decomposing the tetraoxane into two molecules with 
different but supportive roles: one with the formation of radicals from the endoperoxide 
structure represented in blue in the Figure 1.11, which will contribute to increase the 
oxidative stress. On the other hand, an -unsaturated aldehyde, represented in red in the 
Figure 1.11, which can react with nucleophilic biomolecules essential for the parasite, 
acting as inhibitor of TR or falcipain enzymes. Pursuing this idea, cinnamaldehyde was 
chosen as our starting reagent, since it is an -unsaturated aldehyde that can act as TR or 
falcipain inhibitor. The benzaldehyde has the major advantage of being easily 
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functionalized, allowing the opportunity to have structural diversity for the synthesis of 
several compounds for our library. Moreover, all the substituents were in the para position 
of the phenyl group, once it has already shown good antimalarial activities.104  
In addition, other objective of this work is to prove that trans-cinnamaldehyde is 
released, using biomimetic conditions, by activation in the presence of iron (II) bromide. 
Finally, the biological activity of hybrid compounds will be assessed. 
 
 
  
  
 
 
 
 
 
 
Chapter 2 
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2. Synthesis of 1,2,4,5-tetraoxanes 
derived from trans-cinnamaldehyde 
 
As already mentioned, the tetraoxane moiety is a critical pharmacophoric group for 
antimalarial activity. This class of compounds can eventually also be used against other 
parasites such as Leishmania. In this chapter, we describe the design and synthesis of new 
hybrid molecules containing a 1,2,4,5-tetraoxanes. Scheme 2.1 allowed the observation of 
the retrosynthetic analysis, were trans-cinnamaldehyde, an , -unsaturated carbonyl 
compound, and the other starting reagents, an aldehyde or ketone, were selected in order to 
obtain a small library with a range of stability, lipophilicity, and more importantly 
antiparasitic activity. 
 
Scheme 2.1  Retrosynthetic analysis for the synthesis of 1,2,4,5-tetraoxanes derived from trans-cinnamaldehyde 
 
Several methodologies have already been described for the synthesis of this type of 
compounds, however, due to simplicity, efficiency, and relatively low price of reagents, we 
used the synthesis of tetraoxanes according to  et al 
(Scheme 2.2).101,105 
 
Scheme 2.2  Methodology for the synthesis of tetraoxanes 
i) HCO2H, CH3CN, H2O2 50%, r.t.; ii) Re2O7, trans-cinnamaldehyde, CH2Cl2, 0ºC 
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1,2,4,5-Tetraoxanes were prepared using a two-step synthesis depicted in Scheme 
2.2. In the first step, appropriate aldehyde or ketone after acid-catalysis condensation with 
formic acid, react with hydrogen peroxide 50% to give the corresponding gem-
dihydroperoxide, as it can be seen in Scheme 2.3.  
 
 
Scheme 2.3  Proposed reaction mechanism for the synthesis of 1,2,4,5-tetraoxanes 
In the final step, the gem-dihydroperoxide intermediate reacts with the complex 
previously formed between the catalyst rhenium (VII) oxide and the trans-cinnamaldehyde, 
allowing the complete conversion to the 1,2,4,5-tetraoxane. 
 
2.1 Synthesis of tetraoxanes hybrids derived from p-benzaldehyde  
 
In this thesis, a small library of tetraoxanes-based hybrid compounds was 
synthesized, using the technique described above, by varying benzaldehyde moiety. All 
compounds were purified by column chromatography with moderate yields (Table 2.1), 
and were characterized by uni- and bi-dimensional NMR techniques, such as 1H NMR, 
Inducing oxidative stress in parasites
COSY (Correlation Spectroscopy), 13C NMR, APT (Attached Proton Test), HMQC 
(Heteronuclear Multiple Quantum Correlation) and melting point determination. 
 
Table 2.1  Synthesized tetraoxane hybrids derived from p-benzaldehyde, theoretical Log P, yields and melting point 
determination 
Compound R Log Pa Yield (%) m.p. (ºC) 
21 H 3.96 44 134-136 
22 Cl 4.63 39 171-173 
23 Br 4.76 15 196-198 
24 F 4.12 47 158-160 
25 CH3 4.40 20 166-168 
26 CF3 4.85 39 163-165 
27 OCF3 4.92 33 155-157 
a calculated by software http://www.molinspiration.com/cgi-bin/properties 
 
As example, the assignment for compound 22 will be presented in this chapter. The 
full characterization of all the other compounds is available in chapter 5 and 7. 
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Figure 2.1  Chlorobenzaldehyde-tetraoxane 22 1H NMR spectra (CDCl3) 
 
Regarding 1H NMR spectra (Figure 2.1), aromatic signals from phenyl rings at a 
downfield shift, corresponding to 9 protons, appeared as a multiplet between a 1H chemical 
shift ( H) value of 7.45 to 7.35 ppm. The assignment of the chemical shifts on the aliphatic 
region, reveals two vinylic protons attributed to H14 and H15, with H values of 7.03 ppm 
and 6.01 ppm, as a doublet (d) and a double-doublet (dd), respectively. As it can be seen in 
2D NMR COSY spectra (Figure 2.2), proton H15 interacts with proton H14 and H18 with 
a vicinal coupling constant of 16.3 Hz and 6.4 Hz, respectively, while proton H14 only 
interacts with H15, exhibiting the coupling constant of 16.3 Hz. This is characteristic of the 
trans configuration. The signal with H value of 6.58 ppm correspond to proton H18, once 
the COSY spectra reveals its interaction with H15 with a vicinal coupling constant of 6.4 
Hz. The last signal, integrating for 1 proton, correspond to proton H21, which appeared as 
a singlet with H value of 6.78 ppm. Additionally, 1H NMR signals are in agreement with 
the chemical structure of compound 22 and have adequate integrals to fit the 13 protons. 
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Figure 2.2 - Chlorobenzaldehyde-tetraoxane 22 COSY spectra (CDCl3) 
 
Compound 22 has a total of 16 carbons, but it only was expected 12 signals in 13C 
NMR spectra, since the pairs C2-C6, C3-C5, C8-C12, and C9-C11 are equivalent and 
belonging to both aromatic rings. However, the 13C NMR (Figure 2.3) only shows 11 
signals, which means that two of them are overlapped. The aromatic carbons correspond to 
13C chemical shifts ( C) 129.66, 129.14, 128.83, and 127.32 ppm.
To identification of quaternary carbons (Cq) it was required an APT spectrum (Figure 
2.3), which shows the signals of primary and tertiary carbons as positive peaks (pointed 
upward), and the signals of secondary and quaternary carbons as negative peaks (pointed 
downwards). Once tetraoxane 22 only has quaternary and tertiary carbons, the 
identification of the chemical shifts to the three quaternary carbons correspond to C of 
137.47, 134.67, and 129.43 ppm. 
H 14 H 15 H 18 
H 21 
H 15 
H 18 
H 21 
H 14 
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Figure 2.3 - Chlorobenzaldehyde-tetraoxane 22 APT and 13C NMR spectrum (CDCl3) 
 
For complete assignment of carbon signals, it was performed 1H-13C 
heterocorrelation experiments (HMQC  Heteronuclear Multiple Quantum Correlation, 
Figure 2.4). Regarding to C14 and C15, C 
of 116.44 C of 140.71 ppm. Finally, the tetraoxane core can 
C of 107.22 ppm, and 
107.29 ppm, respectively. 
 
C 18 
C 21 
C 15 C 14 
Cq 
APT 
13C NMR 
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Figure 2.4 - Chlorobenzaldehyde-tetraoxane 22 HMQC spectra (CDCl3) 
 
Using Heteronuclear Multiple Bond Correlation Spectroscopy (HMBC, Figure 2.5), 
it was possible to conclude that the Cq C of 137.47 ppm correspond to C4, once it is 
coupled at distance only with a phenyl group. The Cq C of 134.67 ppm only interact 
at distance with H15, which means that it could only correspond to C13. Finally, as it can 
be seen in this spectrum, the Cq C of 129.43 ppm can couple at distance with both 
aromatic ring and H21, corresponding to C7. 
In addition to the NMR spectroscopy, all the compounds were characterized through 
melting point determination (Table 2.1). For all of them, the melting point determination 
range was lower than 2ºC, revealing the pure degree of the synthesized compounds. 
H 15 H 18 
H 21 
H 14 
C 18, 21 
C 15 
C 14 
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Figure 2.5 - Chlorobenzaldehyde-tetraoxane 22 HMBC spectra (CDCl3) 
 
In Table 2.2 is presented a summary of H for all tetraoxanes hybrid compounds 
synthesized. 
 
Table 2.2  1H chemical shift of synthesized hybrid tetraoxanes derived from p-benzaldehyde 
 ; multiplicity  
Compound CH Ar CH=CH-Ar HCOO OOCH CH=CH-Ar CH3 
21 7.53-7.3; m 7.05; d 6.84; s 6.62; dd 6.05; dd - 
22 7.47-7.33; m 7.03; d 6.78; s 6.57; dd 6.01; dd - 
23 7.53-7.23; m 6.94; d 6.69; s 6.49; dd 5.92; dd - 
24 
7.51-7.35; m 
7.12; t 
7.03; d 6.79; s 6.58; dd 6.02; dd - 
25 7.35-7.12; m 6.92; d 6.67; s 6.48; dd 5.92; dd 2.28; s 
26 8.05-7.69; m 7.51; d 7.29; s 7.06; dd 6.48; dd - 
27 7.57-7.28; m 7.05; d 6.83; s 6.60; dd 6.03; dd - 
 
 
H 15 H 18 
H 21 
H 14 
C 18, 21 
C 15 
C 14 
C 7 
C 13 
C 4 
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During the synthesis of compound 21 it was observed the formation of 1,2,4,5,7,8-
hexaoxonane as a side product (Figure 2.6).  
 
Figure 2.6  Chemical structure of 1,2,4,5,7,8-hexaoxonane 
 
After several modifications in the amount of H2O2 throughout the first step of the 
synthesis, it was observed that an excess of H2O2 leads to the formation of this trimer. This 
observation has also been reported by other groups.106  
 
Figure 2.7  1,2,4,5,7,8-Hexaoxonane 1H NMR spectra (CDCl3) 
H 13 H 5 H 12 
H 2 / H 8 
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In the 1H NMR spectra (Figure 2.7) it is possible to observe that instead of a multiplet 
that integrate to 10 protons regarding to the two aromatic rings, a signal appeared as a 
downfield shift multiplet integrating to 15 protons, what opens the hypothesis of three 
aromatic rings, instead of the two predicted. 
Moreover, 1H NMR spectra shows an extra singlet integrating to 1 proton. These two 
singlets correspond to H2 and H8 with H of 7.02 and 6.86 ppm. This observation confirms 
the hypothesis of the trimer formation, with two molecules of benzaldehyde and one of 
cinnamaldehyde. 
 
Table 2.3  Conditions tried for the synthesis of tetraoxane hybrids 28-32 
 
Compound R 
n(mmol) 
H2O2 
Time (h) 
t1               t2 
28 OH 
23 3 3 
11 3 5 
45 7 7 
29 N(CH3)2 23 1.5 3 
30 NO2 
23 3 3 
45 3 3 
45 7 7 
31 OCH2Ph 
23 3 3 
45 3 3 
45 7 7 
32 OCH2CH=CH2 
23 3 3 
45 3 3 
t1 and t2  reaction times for the first and second step of the synthesis respectively 
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Besides the tetraoxanes 21-27 synthesized with yields between 15 and 47%, other 
compounds were tried to be synthesized but without success. From these attempts it can be 
rationalized that the intermediate gem-dihydroperoxide in the substituted benzaldehyde is 
formed, based on thin-layer chromatography (TLC). However, it was not possible to 
quantify the intermediate formed, since it cannot be isolated, due to the instability of the 
gem-dihydroperoxide.107 Nevertheless, the problem seems to appear in the second step of 
the synthesis, since there was no evidence of the tetraoxane formation neither by TLC nor 
in NMR experiences. 
With the aim to synthesize the tetraoxanes 28-32, several attempts were made 
changing the amount of H2O2 and the reaction time (Table 2.3). 
Higher temperature and reactions overnight were avoided due to the instability of 
tetraoxanes. Moreover, it has already been reported that the reaction of hydroperoxidation 
of aromatic aldehydes is long and quite complicated. Adding the fact that symmetric 
tetraoxanes are more easily formed than asymmetric ones.108 Also, powerful electron-
withdrawing substituents on aromatic aldehydes, such as 4-nitrobenzaldehyde, are 
unfavorable as very long reaction times are demand to convert to gem-dihydroperoxide, 
leading to its decomposition.107,109 All of that can explain why we were not able to obtain 
this set of compounds. 
 
A second group of compounds were tried to be synthesize, using para-substitute 
cinnamaldehyde, as it can be seen in Figure 2.8. 
 
Figure 2.8  Tetraoxane designed with p-substituents in cinnamaldehyde 
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The same synthetic route as described above (Scheme 2.2) was followed for the 
synthesis of these two compounds. Compound trans-4-(trifluoromethyl)cinnamaldehyde 
was not commercially available, so the reduction of the available trans-cinnamic acid to 
the correspondent aldehyde was performed. Briefly, trans-4-(trifluoromethyl)cinnamic 
acid reacted with TBTU and TEA, followed by the reaction with N,O-
dimethylhydroxylamine to give the intermediate hydroxamate, which was confirmed by 1H 
NMR. In the final step, the intermediate was reduced with LiAlH4 to give trans-4-
(trifluoromethyl)cinnamaldehyde (Scheme 2.4). 
 
Scheme 2.4  Synthetic methodology for the synthesis of trans-4-(trifluoromethyl)cinnamaldehyde. 
i) TBTU, TEA, N,O-dimethylhydroxylamine, CH2Cl2, r.t.; ii) LiAlH4, THF, 0°C, N2. 
 
The synthesis of compound 33 was accomplished (Table 2.4), however after 
purification with flash column chromatography, the compound was not isolated. 
 
Table 2.4 Conditions tried for the synthesis of tetraoxane hybrids derived from substituted p-cinnamaldehyde
Compound R 
Time (h) 
t1               t2 
33 CF3 3 3 
34 OCH3 
3 3 
3 4 
3 5 
7 6 
t1 and t2  reaction times for the first and second step of the synthesis, respectively
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For compound 34 were made some changes in reactions times in the first and second 
step of the synthesis, as described in Table 2.4. The first attempt to synthesize compound 
34 was similar to the synthesis previously described, using 3 hours reaction for both steps. 
Nevertheless, the synthesis of this compound was not possible. To overcome the problem, 
the time of the second step of the reaction was increased, since TLC of the first step showed 
the formation of the intermediate gem-dihydroperoxide. However, this change did not lead 
to the formation of the final tetraoxane. 
A new and successful attempt was made increasing both reaction times, in which t1 
and t2 were 7 and 6 hours, respectively. In this case, the first step was longer, comparing 
with the first attempt of only 3h. However, after purification using flash chromatography 
no pure compound 34 was isolated. 
Since the gem-dihydroperoxide was not quantified for reasons already explained 
above, probably the synthesized amount of this intermediate in the first attempts was not 
enough to proceed the second step with good yields.  
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2.2 Synthesis of tetraoxanes hybrids with improved solubility 
 
In order to improve water solubility, a new set of compounds were synthesized. The 
rationale was to incorporate ionizable groups or groups with a higher sp3 content (Table 
2.5). 
Table 2.5  Possible hybrid tetraoxanes to be synthesized and its theoretical Log P  
Compounds R Log Pa 
35 3.18 
36 
 
4.26 
37 3.98 
38 
 
5.21 
39 
 
5.51 
 a calculated by software http://www.molinspiration.com/cgi-bin/properties 
 
In order to obtain adamantanone-2-carbaldehyde from 2-adamantanone it was 
necessary a Wittig-Horner reaction followed by hydrolysis in acidic conditions, as it can 
be seen in Scheme 2.5.110  
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Scheme 2.5  Synthetic methodology for the synthesis of adamantanone-2-carbaldehyde 
 
Reaction conditions were optimized in order to obtain compounds 35-39. In 
particular, the number of molar equivalents of H2O2, the reaction time and temperature of 
each step of the tetraoxane synthesis, and the solvent used in the second step, as presented 
in Table 2.6. Once more, high temperatures and long reactions overnight were avoided due 
to the reactivity of peroxides. 
Compound 36 was designed as a precursor of a secondary amine (piperidine) by 
removing the benzyl group via hydrogenation. Such piperidine derivative would have a log 
P value of 2.27 which is significantly more polar than the remaining tetraoxanes. This could 
also improve water solubility, and thus oral absorption when compared to more lipophilic 
tetraoxanes. The pyrrole derivative 35 was also selected for its polarity. Unfortunately, 
none of the methods afforded compounds 35 and 36. Since the corresponding gem-
dihydroperoxide are more polar when compared from the previous series, we hypothesized 
that dichloromethane (DCM), used as solvent in the second step of tetraoxane synthesis, 
could be replaced by the more polar solvents ethyl acetate or trifluoroethanol. However, 
none of the modifications afforded the expected target compound. 
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Table 2.6  Conditions tried for the synthesis of other hybrid tetraoxanes 
Compound 
n(mmol)  
H2O2 
Time (h) Temp (ºC) Solvent 
t1 t2 T2 S2 
35 
23 1 3 0 
DCM 
23 1.5 3 r.t. 
36 
23 3 3 0 DCM 
23 3 3 0 THF 
4 3 120 r.t CF3CH2OH 
37 
23 3 3 
r.t. 
DCM 
4 3 3 CF3CH2OH 
23 3 4 
0 
CF3CH2OH 
45 3 3 CF3CH2OH 
38 
23 3 3 
0 
DCM 23 6 3 
23 3 3 r.t. 
39 23 2 3 r.t. DCM 
t1- reaction time for the first step of the synthesis; t2- reaction time for the second step of the 
synthesis; T2- temperature during the second step of the synthesis; S2- solvent used during the 
second step of the synthesis 
 
For compounds 37-39, the reaction mixtures were complex, and we were not able 
to obtain the desired compounds with adequate purity. 
 
  
 
 
 
 
 
 
Chapter 3 
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3. Biomimetic activation and 
antiparasitic activity 
 
3.1 Activation of tetraoxanes with iron (II) 
 
 The hybrid compounds were designed to act by two different mechanisms of action. 
The endoperoxide bond can be activated by iron (II) into radicals leading to the increase of 
the oxidative stress. In addition, this activation lead to the formation of an -unsaturated 
compound, trans-cinnamaldehyde, (Scheme 3.1) that can react with nucleophiles causing 
the possible inhibition of TR or falcipain, in leishmaniasis and malaria, respectively. To 
evaluate this hypothesis, we monitored by HPLC the activation of the compounds by 
incubate them in the presence of iron (II) bromide. 
Scheme 3.1  Activation of tetraoxanes with FeBr2 
 
For the HPLC studies of the tetraoxanes 21-27, a column RP-18e (5 m) was used, 
isocratic gradient with MeOH/H2O (95:5) as eluent with a flow rate of 1.0 mL/min, and 
wavelength of 264 nm. 
Table 3.1 shows the retention times (Rt) obtained for the aldehydes used as starting 
reagents and hybrid tetraoxanes 21-27. 
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Table 3.1  Retention times for tetraoxanes synthesized and respective aldehydes 
Compounds 
Retention 
time (min) 
Aldehydes 
Retention 
time (min) 
  20 2.48 
21 3.54 Benzaldehyde 2.46 
22 3.59 4-Chlorobenzaldehyde 2.53 
23 3.99 4-Bromobenzaldehyde 2.64 
24 3.25 4-Fluorobenzaldehyde 2.43 
25 3.55 p-Tolualdehyde 2.64 
26 3.52 4-(Trifluoromethyl)benzaldehyde 2.42 
27 3.30 4-(Trifluorometoxy)benzaldehyde 2.49 
 
Fresh solutions containing tetraoxane, iron (II) bromide, and ACN/H2O were kept in 
a thermostated bath at 25ºC. Activation assays were done in triplicate and calibration curves 
were also obtained for all compounds. Figure 3.1 shows the calibration curve of compound 
22, in which is possible to see a direct proportionality between concentration and area. 
 
 
Figure 3.1  Calibration curve of tetraoxane 22 
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The reaction of activation was monitored for 2 h by HPLC, in which is possible to 
observe the disappearance of the hybrid tetraoxane and the appearance of a new compound 
with a lower Rt, coincident to both cinnamaldehyde and parental aldehydes.  The results 
for all the compounds were identical, so the interpretation of the results was only done for 
compound 22 (Figure 3.2). 
 
 
Figure 3.2  Activation of tetraoxane 22 with iron (II) bromide 
  
The graph in Figure 3.3 summarizes the results obtained, in which is possible to see 
the disappearance of compound 22 in blue and the appearance of a new compound in red.   
 
t=0h t=0.5h t=1h 
t=1.5h
t=2h 
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Figure 3.3  Time-dependence profile for the activation of tetraoxane 22 
 
The rate constant (kobs) for the decreasing of compound 22 is given by the slope of a 
linear regression of Ln(Area) vs time. (Figure 3.4).  
 
Figure 3.4  Kinetic of the disappearance of tetraoxane 22 throughout time 
 
This HPLC studies were made in pseudo first-order conditions, once the 
concentration of iron (II) bromide was much higher than the concentration of the substrate 
(tetraoxanes 21-27). 
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Rate constant and half-life time (t1/2) of the compounds were determined through 
Equation 1 and 2, respectively. Table 3.2 has a summary of all the calculated half-lives 
times for tetraoxanes 21-27. 
 
, in which    
 
 
 
Table 3.2  Half-lives times and rate constant of the hybrid compounds 21-27 
Compound kobs (h-1) a t1/2 (min) a 
21 2.76 15.6 
22 3.35 13.2 
23 3.23 13.2 
24 2.40 17.4 
25 3.27 13.2 
26 2.35 18 
27 2.06 21 
a calculated through the average of the three assays 
 
The kinetic of activation revealed a complete consumption of all the hybrid 
compounds and appearance of trans-cinnamaldehyde and their respective aldehydes. 
However, the quantification of these products was not accomplished since both compound 
have similar Rt. Trans-cinnamaldehyde, as an , -unsaturated compound, can act as 
inhibitor of TR or falcipain, which are enzymes that play a key role in leishmaniasis and 
malaria, respectively. Moreover, these compounds have demonstrated small half-lives 
times which indicates that they are rapidly activated by iron (II), so it is expected that they 
have similar behavior when it comes to in vivo studies. 
 
Equation 1 
Equation 2 
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3.2 Antiparasitic activity  
 
The tetraoxanes synthesized were evaluated against Plasmodium falciparum Dd2 and 
3D7 which is a strain resistant to both chloroquine and mefloquine, and a strain sensitive 
to both chloroquine and mefloquine, respectively. These studies were carried out in the 
Institute of Hygiene and Tropical Medicine (Universidade Nova de Lisboa), following a 
reported protocol and briefly described in chapter 5.111 
The results of their inhibitory activity are summarized in Table 3.3 for P. falciparum 
Dd2 and 3D7 strains, and are expressed in IC50, which means the concentration of the drug 
that inhibits 50% of the parasite growing.  
 
Table 3.3  IC50 values for tetraoxanes 21-27 in P. falciparum Dd2 and 3D7 strains 
 IC50 ( M) 
Compound Dd2 3D7 
21 1.34 1.67 
22 0.68 2.06 
23 0.42 1.36 
24 1.65 1.20 
25 0.74 0.59 
26 0.63 1.02 
27 1.64 3.07 
Chloroquine 0.36 0.02 
 
 
Compounds 22, 23, 25 and 26 revealed the best inhibition action in P. falciparum 
Dd2 strains, with IC50 values ranging between 0.42 and 0.74 M. Compounds 21, 24 and 
27 revealed to inhibit with less efficacy P. falciparum Dd2 strains, what can be seen by 
their IC50 values ranging between 1.34 and 1.65 M. 
Compound 25 revealed the best inhibition in P. falciparum 3D7 strains, with IC50 
value of 0.59 M. The remaining compounds revealed to inhibit with less efficacy P. 
falciparum 3D7 strains, what can be seen by their IC50 values ranging between 1.02 and 
3.07 M. 
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Hybrid compounds have demonstrated to be moderately active, showing better 
inhibition results against Plasmodium falciparum Dd2 strain, in which several compounds 
revealed sub- M values. 
 
As mentioned previously, TR is a cysteine dependent oxy-reductase crucial to 
maintain the redox balance in Leishmania spp.. To evaluate the potential as antileishmanial 
agents, the compounds were screened at Francisco Gamarro Lab, Instituto de Parasitologia 
y Bi -  
The compounds were tested against the promastigote form of Leishmania donovani, 
in which under the conditions used some compounds have shown solubility issues. All 
compounds tested did not shown activity, even at the higher concentration tested of 1 mM. 
These results can indicate that: i) the compounds do not have activity against the 
promastigote form of L. donovani; ii) the compounds are unable to cross the plasmatic 
membrane of parasites; iii) the compounds are not well dissolved in the media used and, 
consequently, precipitated. 
Based in the results obtained, less lipophilic compounds should be synthesized and 
tested against promastigote and amastigote forms of L. donovani.

 
 
 
 
 
 
Chapter 4 
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4. Conclusions and future work 
 
4.1 Conclusions 
 
The main objective of this thesis was to prepare a small library of hybrid compounds 
with 1,2,4,5-tetraoxane scaffold that, upon activation by intracellular iron(II), can 
selectively deliver an electrophile capable of reacting with essential enzymes of the 
parasites causing leishmaniasis and malaria. The electrophile is an , -unsaturated 
aldehyde that has the potential to react via Michael addition with the catalytic cysteine 
residues of trypanothione reductase for leishmaniasis and falcipain for malaria. 
Seven 1,2,4,5-tetraoxanes were synthesized in moderate yields by first reacting the 
appropriate benzaldehyde with hydrogen peroxide, and then converting the resulting gem-
dihydroperoxide into the final product by reaction with trans-cinnamaldehyde in the 
presence of rhenium (VII) oxide. The chemical structure of tetraoxanes was confirmed 
through unidimensional - 1H NMR, 13C NMR  and bidimensional  COSY, HMQC, and 
HMBC  NMR spectroscopy. Since the initial compounds displays high lipophilicity and 
low solubility, a second set of tetraoxanes were designed to incorporate solubility-
conferring structural features such as amines and 5-membered heterocyclic moieties. 
Unfortunately, all attempts to synthesize these compounds failed, suggesting that the 
synthetic method has stringent structural requirements that limit its usefulness. 
The activation of tetraoxanes was studied by monitoring the reaction of compounds 
with iron(II) by HPLC. Incubation of tetraoxanes with FeBr2 in ACN/H2O led to complete 
consumption of the starting material and the formation of the corresponding benzaldehyde 
and cinnamaldehyde, thus confirming that iron (II) efficiently activates this class of 
endoperoxides. The half-lives times for activation ranged from 13 to 21 minutes, indicating 
that the reaction is not significantly affected by the substituents on the benzaldehyde 
moiety. This is consistent with a radical based mechanism, in which the initial oxygen-
centered radicals are poorly stabilized by the substituents. Overall, these studies were a 
proof-of-concept showing that a , -unsaturated carbonyl compound is rapidly released 
upon activation of tetraoxane by iron (II), suggesting that these endoperoxides would have 
similar behavior in vivo. 
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Tetraoxanes were screened against the chloroquine-sensitive and chloroquine-
resistant Plasmodium falciparum strains, 3D7 and Dd2 respectively, showing IC50 values 
in the sub-micromolar range for Dd2 strain. The results are consistent with efficient 
activation of tetraoxanes in the infected erythrocytes to generate toxic radical species and 
the release of cinnamaldehyde. Unfortunately, the tetraoxanes were not soluble in the 
conditions used for the screening against Leishmania donovani, thus precluding evaluation 
as antileishmanial agents. 
 
4.2 Future Work 
 
The work reported in this thesis is a novel approach, in the context of selective 
antiparasitic agents. As Leishmania and Plasmodium parasite mobilize relatively high 
amounts of iron during critical steps of their life-cycle, it is expected that tetraoxanes can 
be activated in similar ways in both parasites. 
The major challenge that needs to be addressed in the future is the poor solubility and 
high lipophilicity displayed by tetraoxanes. Different approaches can be envisaged to 
overcome the problems faced in preparing more polar derivatives. First, a different set of 
substituents could be used in the benzaldehyde or cinnamaldehyde starting materials, such 
as carboxylic acid (or an ester that can be subsequently hydrolyzed) or an amide. Secondly, 
optimization of the synthetic method could be performed in order to extend its scope. 
Thirdly, encapsulation in nanoparticles could be performed as a strategy to improve 
solubility and selective delivery to macrophages. This is particularly attractive for 
leishmaniasis, because Leishmania parasites tend to accumulate in these cells. 
Future work should also involve a more detailed kinetic study of tetraoxane activation 
in infected cells in order to evaluate if rates of delivery of the electrophiles are identical to 
those determined in the biomimetic experiments. Including, more substituents in both sides 
of the tetraoxane scaffold would also improve our understanding of the structural 
requirements for rapid and efficient activation. 
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5. Materials and Methods 
 
5.1 Equipment 
 
NMR spectra were recorded in a Bruker 300 Ultra Shield. Chemical shifts values of 
H and C are reported in parts per million (ppm), using d3-chloroform as internal reference. 
Coupling constants (J) are reported in hertz (Hz). 
Melting points were determined on a Kofler Bock Monoscop M. camera and are 
uncorrected. 
UV-visible spectra were record in 1 cm pathlength quartz cuvettes at 25 ºC using a 
Shimadzu UV-1603 UV-visible spectrophotometer. 
HPLC data were obtained on a Hitachi Elite Lachrom with a L-2130 pump, a L-2300 
column oven, a Rheodyne injector of 20 L, and a L-2400 UV-detector. The column used 
was a LichroCart ® RP-18E 250-4 purospher ®STAR with a guard column RP-18E. 
 
5.2 Chromatography 
 
Thin-layer chromatography (TLC) was performed using coated silica gel plates from 
Merk Kieselgel 60 F254, 200 m thickness. Visualization was carried out by a CAMAG UV 
lamp at a wavelength of 254 nm and 366 nm, and revealed with iodine, p-anisaldehyde and 
ninhydrin dip. 
Purification of compounds by column chromatography was performed using silica 
gel 60 M, 0.040-0.063 mm from Merk. 
Purification of compounds by preparative thin-layer chromatography were performed 
in coated silica-gel plates, silica gel 60 GF254, 0.040-0.063 mm, from Merk. 
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5.3 Reagents and Solvents 
5.3.1 Reagents 
All the reagents used during the experimental synthesis were of analytical grade and 
were purchased from Sigma-Aldrich, Alfa Aesar, and Merk and used without further 
purification. 
 
5.3.2 Solvents 
Solvents used were of analytical grade. Dichloromethane (DCM) and acetonitrile 
(ACN), were dried from calcium chloride and from phosphorous pentoxide, respectively, 
and distilled at atmospheric pressure. Tetrahydrofuran was distilled from sodium-
benzophenone system. All the solvents used in purification were distilled under reduced 
pressure. 
NMR analysis were performed using chloroform deuterated (CDCl3) with a degree 
of purity higher than 95%. 
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5.4 Synthesis of 1,2,4,5-tetraoxanes derivatives and it structural 
characterization  
 
General procedure for the synthesis of 21-27: 
To a stirring solution of the appropriate benzaldehyde (0.9 mmol; 1 equiv.) in dry 
acetonitrile (1.3 mL) was added formic acid (34 equiv.) at 0°C under nitrogen atmosphere. 
Hydrogen peroxide 50% (24 equiv.) was added slowly and then the solution was allowed 
to warm to room temperature and stirred for 2-3 h under nitrogen atmosphere. After 1h of 
reaction, hydrogen peroxide 50% (24 equiv.) was added in the same conditions. The 
solution was diluted with brine solution (10 mL) and extracted with DCM (3 × 15 mL). 
The combined organic layers, containing the gem-dihydroperoxide, were dried over 
anhydrous sodium sulfate, filtered and concentrated under reduced pressure. At 0°C and 
under nitrogen atmosphere the gem-dihydroperoxide intermediate was added to a stirring 
solution of trans-cinnamaldehyde (1.6 equiv.) and rhenium (VII) oxide (0.05 mmol%) in 
dry DCM (1.6 mL). The reaction was followed by TLC, and after 2-3 h at 0°C and under 
nitrogen atmosphere, the mixture was filtered with a plug of silica and concentrated under 
reduced pressure. 
The purification by flash column chromatography on silica gel using DCM:n-Hexane 
(1:1) as eluent gave the pure compound. 
 
 Compound 21 - (E)-3-phenyl-6-styryl-1,2,4,5-tetraoxane 
 Prepared according to the general procedure to give 
21 as a white solid with a yield of 44%, m.p 133-136°C; 
1H NMR (300 MHz, CDCl3): H (ppm) 7.53  7.37 (m, 
10H, Ar(CH)), 7.05 (d, J = 16.3 Hz, 1H, CH=CH-Ar), 6.84 (s, 1H, HCOO), 6.62  
(dd, J = 6.3, 0.6 Hz, 1H, OOCH), 6.05 (dd, J = 16.3, 6.3 Hz, 1H, CH=CH-Ar). 13C NMR 
(75 MHz, CDCl3): C (ppm) 140.47 (CH=CH-Ar), 134.78 (Cq), 131.32 (Ar(CH)), 131.06 
(Cq), 129.57 (Ar(CH)), 128.81 (Ar(CH)),127.80 (Ar(CH)), 127.31 (Ar(CH)), 116.70 
(CH=CH-Ar), 108.08 (HCOO), 107.20 (OOCH). % purity by HPLC: 99% 
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Compound 22 - (E)-3-(4-chlorophenyl)-6-styryl-1,2,4,5-tetraoxane  
Prepared according to the general procedure to 
give 22 as a white solid with a yield of 39%, m.p 171-
173°C; 1H NMR (300 MHz, CDCl3): H (ppm)  
7.47  7.33 (m, 9H, Ar(CH)), 7.03 (d, J = 16.3 Hz, 1H, CH=CH-Ar), 6.78  
(s, 1H, HCOO), 6.58 (dd, J = 6.4, 0.7 Hz, 1H, OOCH), 6.01 (dd, J = 16.3, 6.3 Hz, 1H, 
CH=CH-Ar). 13C NMR (75 MHz, CDCl3): C (ppm) 140.71 (CH=CH-Ar), 137.47 (Cq), 
134.67 (Cq), 129.66 (Ar(CH)), 129.43 (Cq), 129.14 (Ar(CH)), 128.83 (Ar(CH)), 127.32 
(Ar(CH)), 116.44 (CH=CH-Ar), 107.29 (HCOO), 107.22 (OOCH). % purity by HPLC: 
99% 
 
Compound 23 - (E)-3-(4-bromophenyl)-6-styryl-1,2,4,5-tetraoxane  
Prepared according to the general procedure to 
give 23 as a white solid with a yield of 15%, m.p 196-
198°C; 1H NMR (300 MHz, CDCl3): H (ppm)  
7.53  7.23 (m, 9H, Ar(CH)), 6.94 (d, J = 16.2 Hz, 1H, CH=CH-Ar), 6.69 (s, 1H, HCOO), 
6.49 (dd, J = 6.4, 0.8 Hz, 1H, OOCH), 5.92 (dd, J = 16.3, 6.4 Hz, 1H, CH=CH-Ar).  
13C NMR (75 MHz, CDCl3): C (ppm) 140.74 (CH=CH-Ar), 132.10 (Ar(CH)), 134.66 
(Cq), 129.90 (Cq), 129.67 (Ar(CH)), 129.35 (Ar(CH)), 128.84 (Ar(CH)), 127.33 (Ar(CH)), 
125.27 (Cq), 116.41 (CH=CH-Ar), 107.31 (HCOO), 107.18 (OOCH). % purity by HPLC: 
98% 
 
Compound 24 - (E)-3-(4-fluorophenyl)-6-styryl-1,2,4,5-tetraoxane 
Prepared according to the general procedure to 
give 24 as a white solid with a yield of 47%, m.p 158-
160°C; 1H NMR (300 MHz, CDCl3): H (ppm)  
7.51  7.35 (m, 7H, Ar(CH)), 7.12 (t, J = 8.7 Hz, 2H, Ar), 7.03 (dd, J = 16.3 Hz, 1H, 
CH=CH-Ar), 6.79 (s, 1H, HCOO), 6.58 (dd, J = 6.3, 0.6 Hz, 1H, OOCH), 6.02  
(dd, J = 16.3, 6.3 Hz, 1H, CH=CH-Ar). 13C NMR (75 MHz, CDCl3): C (ppm) 166.07 
(Cq), 162.74 (Cq), 140.68 (CH=CH-Ar), 134.68 (Cq), 130.08 (Ar(CH)), 129.96 (Ar(CH)), 
129.66 (Ar(CH)), 128.84 (Ar(CH)), 127.33 (Ar(CH)), 116.17 (Ar(CH)), 115.88 (Ar(CH)), 
116.46 (CH=CH-Ar), 107.28 (HCOO), 107.23 (OOCH). % purity by HPLC: 99% 
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Compound 25 - (E)-3-styryl-6-(p-tolyl)-1,2,4,5-tetraoxane 
Prepared according to the general procedure to 
give 25 as a white solid with a yield of 20%, m.p 166-
168°C; 1H NMR (300 MHz, CDCl3): H (ppm)  
7.35  7.12 (m, 9H, Ar(CH)), 6.92 (d, J = 16.3 Hz, 1H, CH=CH-Ar), 6.67 (s, 1H, HCOO), 
6.48 (dd, J = 6.3, 0.7 Hz, 1H, OOCH), 5.92 (dd, J = 16.3, 6.3 Hz, 1H, CH=CH-Ar), 2.28 
(s, 3H, CH3). 13C NMR (75 MHz, CDCl3): C (ppm) 141.65 (Cq), 140.38 (CH=CH-Ar), 
134.80 (Cq), 129.54 (Ar(CH)), 129.46 (Ar(CH)), 128.80 (Ar(CH)), 128.20 (Cq), 127,76 
(Ar(CH)), 127.29 (Ar(CH)), 116.77 (CH=CH-Ar),108.10 (HCOO), 107.08 (OOCH), 21.50 
(CH3). % purity by HPLC: 98% 
 
Compound 26 - (E)-3-styryl-6-(4-(trifluoromethyl)phenyl)-1,2,4,5-
tetraoxane 
Prepared according to the general procedure to 
give 26 as a white solid with a yield of 39%, m.p 163-
165°C; 1H NMR (300 MHz, CDCl3): H (ppm)  
8.05  7.69 (m, 9H, Ar(CH)), 7.51 (d, J = 16.3 Hz, 1H, CH=CH-Ar), 7.29 (s, 1H, HCOO), 
7.06 (dd, J = 6.4, 0.7 Hz, 1H, OOCH), 6.48 (dd, J = 16.3, 6.4 Hz, 1H, CH=CH-Ar). 13C 
NMR (75 MHz, CDCl3): C (ppm) 151.20 (CF3), 140.78 (CH=CH-Ar), 134.64 (Cq), 
129.68 (Ar(CH)), 129.56 (Ar(CH)), 129.48 (Cq), 128.84 (Ar(CH)), 127.33 (Ar(CH)), 
122.03 (Cq), 121.05 (Ar(CH)), 116.36 (CH=CH-Ar), 107.33 (OOCH) and 107.01 (HCOO). 
% purity by HPLC: 98% 
 
Compound 27 - (E)-3-styryl-6-(4-(trifluoromethoxy)phenyl)-1,2,4,5-
tetraoxane 
Prepared according to the general procedure 
to give 27 as a white solid with a yield of 33%, m.p. 
155-157°C; 1H NMR (300 MHz, CDCl3): H 
(ppm) 7.57  7.28 (m, 9H, Ar(CH)), 7.05 (d, J = 16.3 Hz, 1H, CH=CH-Ar), 6.83 (s, 1H, 
HCOO), 6.60 (dd, J = 6.4, 0.6 Hz, 1H, OOCH), 6.03 (dd, J = 16.3, 6.4 Hz, 1H,  
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CH=CH-Ar). 13C NMR (75 MHz, CDCl3): C (ppm) 151.18 (OCF3), 140.78  
(CH=CH-Ar), 134.64 (Cq), 129.68 (Ar(CH)), 129.55 (Ar(CH)), 129.48 (Cq), 128.84 
(Ar(CH)), 127.32 (Ar(CH)), 122.03 (Cq), 121.05 (Ar(CH)), 116.35 (CH=CH-Ar), 107.33 
(OOCH), 107.00 (HCOO). % purity by HPLC: 99% 
 
5.5 Synthesis of trans-4-(trifluoromethyl)-cinnamaldehyde 
 
To a stirring solution of trans-4-(trifluoromethyl)cinnamic 
acid (0.84 mmol) in DCM (3 mL) was added TBTU (1 equiv.)  
and TEA (1 equiv.) at room temperature. After 30 minutes of 
reaction, N,O-dimethylhydroxylamine (1.1 equiv.) and TEA  (1 equiv.) were added. The 
stirring continued overnight at room temperature, then the mixture was diluted with DCM 
(20 mL) and washed with NaHCO3 (2 × 20 mL) and brine solution (2 × 20 mL). The 
combined organic layers, were dried over anhydrous sodium sulfate, filtered and 
concentrated under reduced pressure to give the Weinreb amide intermediate. The 
compound was purified by flash column chromatography on silica gel using EtOAc:n-
Hexane (1:1). In the second step, to the stirring solution of the intermediate in dry THF (8 
mL) was slowly added LiAlH4 (1 equiv.) at 0°C under nitrogen atmosphere. The reaction 
was followed by TLC and after completion a solution of potassium hydrogenosulfate (2 
equiv.) in water (2 mL) was added. The mixture was diluted with water (40 mL) and 
extracted with diethylic ether (3 × 30 mL). The combined organic layers were washed with 
NaHCO3 (3 × 30 mL) and brine solution (3 × 30 mL) and dried over anhydrous sodium 
sulfate, filtered and concentrated under reduced pressure, to give an orange oil. 
 
5.6 Synthesis of adamantane-2-carbaldehyde 
 
Methoxymethyltriphenylphosphonium (5.8 mmol; 1.4 equiv.)  and 
potassium bis(trimethylsilyl)amide (0.5M in hexane, 11.66 mL) were added 
in dry THF (7.5 mL) at 0 ºC under nitrogen atmosphere.  After 15 minutes, 
2-adamantanone (1 equiv) in dry THF (2.5 mL) was added. The stirring continued for 2h 
at 0 ºC, then the mixture was diluted with water (30 mL) and extracted with diethyl ether 
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(3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered and concentrated under reduced pressure. The crude was dissolved into ACN (25 
mL) and HCl (1 M; 6.3 mL) was added. After 21 h at room temperature the solution was 
diluted with brine solution (30 mL) and extracted with diethyl ether (3 × 30 mL) and the 
combined organic layers dried over anhydrous sodium sulfate, filtered and concentrated 
under reduced pressure, to give pure compound. White solid, 35% yield, m.p 130-132°C; 
1H NMR (300 MHz, CDCl3): H (ppm) 10.11 (s, 1H, COH), 2.78 (s, 3H), 2.34-2.01 (m, 
12H). 
 
5.7 Activation of tetraoxanes with iron bromide 
 
Stock solutions of compounds 21-27 (10 mM in ACN), iron (II) bromide (100 mM 
in H2O) were freshly prepared. For the activation assays, in an eppendorf kept in a water 
bath at 25 ºC and containing 200 L of compounds 21-27 (1 mM) and 1.44 mL of ACN/H2O 
(1:1) were added 360 L of iron (II) bromide (18 mM). The activation begins when iron 
(II) bromide was added (t=0) and several aliquots were injected in the HPLC system during 
2h.103 
Chromatographic separation was achieved using a RP-18e (5 m) column and 
isocratic gradient with MeOH/H2O (95:5) at a 1.0 mL/min flow rate. The activation was 
monitored at 264 nm wavelength obtained from the maximum absorption from the UV-
visible spectra of compounds 21-27. 
The activation assays were done in triplicate and calibration curves were also 
obtained for all compounds. 
 
5.8 In vitro antimalarial assays 
 
Dd2 and 3D7 strains were cultured using human erythrocytes suspension with a 5 % 
hematocrit and maximal parasitemia of 5 %. The cultures were set up in microplates and 
synchronized by double sorbitol treatment prior to the assays. To determine the 
correspondent IC50, Dd2 and 3D7 strains were cultivated for 48 h in the presence of 
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different concentrations of tetraoxanes, then a solution of SYBR Green was added to each 
well and incubated for 60 minutes. Fluorescence is collected in a fluorimeter plate reader. 
The activity was determined through parasitemia counting using optical microscopy.111 
 
5.9 In vitro antileishmanial assays  
L. donovani promastigotes with the luciferase gene integrated into the parasite 
genome (Luc line) were grown at 28°C in an RPMI 1640-modified medium (Invitrogen) 
supplemented with 20% heat-inactivated fetal bovine serum (hiFBS, Invitrogen).  The 
antileishmaial activity of compounds was determined measuring the luciferase activity in 
parasites.112 
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7.1  Compound 21  (E)-3-phenyl-6styryl-1,2,4,5-tetraoxane 
Figure 7.1  Benzaldehyde-tetraoxane 21 1H NMR spectra (CDCl3) 
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Figure 7.2  Benzaldehyde-tetraoxane 21 COSY spectra (CDCl3) 
Figure 7.3  Benzaldehyde-tetraoxane 21 13C NMR spectra (CDCl3) 
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Figure 7.4  Benzaldehyde-tetraoxane 21 APT spectra (CDCl3) 
Figure 7.5  Benzaldehyde-tetraoxane 21 HMQC spectra (CDCl3) 
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Figure 7.6  Activation of tetraoxane 21 with FeBr2 
7.2 Compound 22  (E)-3-(4-chlorophenyl)-6-styryl-1,2,4,5-
tetraoxane 
Figure 7.7  Chlorobenzaldehyde-tetraoxane 22 1H NMR spectra (CDCl3) 
t=0h 
t=0.5h t=1h 
t=1.5h
t=2h 
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Figure 7.8  Chlorobenzaldehyde-tetraoxane 22 COSY spectra (CDCl3) 
Figure 7.9  Chlorobenzaldehyde-tetraoxane 22 13C NMR spectra (CDCl3) 
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Figure 7.10  Chlorobenzaldehyde-tetraoxane 22 APT spectra (CDCl3) 
Figure 7.11  Chlorobenzaldehyde-tetraoxane 22 HMQC spectra (CDCl3) 
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Figure 7.12  Chlorobenzaldehyde-tetraoxane 22 HMBC spectra (CDCl3) 
Figure 7.13  Activation of tetraoxane 22 with FeBr2 
t=0h 
t=0.5h t=1h 
t=1.5h t=2h 
Inducing oxidative stress in parasites
7.3  Compound 23  (E)-3-(4-bromophenyl)-6-styryl-1,2,4,5-
tetraoxane 
Figure 7.14  Bromobenzaldehyde-tetraoxane 23 1H NMR spectra (CDCl3) 
Figure 7.15  Bromobenzaldehyde-tetraoxane 23 COSY spectra (CDCl3) 
Inducing oxidative stress in parasites
Figure 7.16  Bromobenzaldehyde-tetraoxane 23 13C NMR spectra (CDCl3) 
Figure 7.17  Bromobenzaldehyde-tetraoxane 23 APT spectra (CDCl3) 
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Figure 7.18  Activation of tetraoxane 23 with FeBr2 
7.4  Compound 24  (E)-3-(4-fluorophenyl)-6-styryl-1,2,4,5-
tetraoxane 
Figure 7.19  Fluorobenzaldehyde-tetraoxane 24 1H NMR spectra (CDCl3) 
t=0h t=0.5h t=1h 
t=1.5h t=2h 
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Figure 7.20  Fluorobenzaldehyde-tetraoxane 24 COSY spectra (CDCl3) 
Figure 7.21  Fluorobenzaldehyde-tetraoxane 24 13C NMR spectra (CDCl3) 
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Figure 7.22  Fluorobenzaldehyde-tetraoxane 24 APT spectra (CDCl3) 
Figure 7.23  Fluorobenzaldehyde-tetraoxane 24 HMQC spectra (CDCl3) 
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Figure 7.24  Activation of tetraoxane 24 with FeBr2 
7.5  Compound 25  (E)-3-styryl-6-(p-tolyl)-1,2,4,5-tetraoxane 
Figure 7.25  p-Tolylbenzaldehyde-tetraoxane 25 1H NMR spectra (CDCl3) 
t=0h 
t=0.5h t=1h 
t=1.5h
t=2h 
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Figure 7.26  p-Tolylbenzaldehyde-tetraoxane 25 COSY spectra (CDCl3) 
Figure 7.27  p-Tolylbenzaldehyde-tetraoxane 25 13C NMR spectra (CDCl3) 
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Figure 7.28  p-Tolylbenzaldehyde-tetraoxane 25 APT spectra (CDCl3) 
Figure 7.29  p-Tolylbenzaldehyde-tetraoxane 25 HMQC spectra (CDCl3) 
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Figure 7.30  Activation of tetraoxane 25 with FeBr2 
7.6  Compound 26  (E)-3-styryl-6-(4-(trifluoromethyl)phenyl)-
1,2,4,5-tetraoxane 
Figure 7.31  Trifluoromethylbenzaldehyde-tetraoxane 26 1H NMR spectra (CDCl3) 
t=0h t=0.5h
t=1h 
t=1.5h t=2h 
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Figure 7.32  Trifluoromethylbenzaldehyde-tetraoxane 26 COSY spectra (CDCl3) 
Figure 7.33  Trifluoromethylbenzaldehyde-tetraoxane 26 13C NMR spectra (CDCl3) 
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Figure 7.34  Trifluoromethylbenzaldehyde-tetraoxane 26 APT spectra (CDCl3) 
Figure 7.35  Trifluoromethylbenzaldehyde-tetraoxane 26 HMQC spectra (CDCl3) 
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Figure 7.36  Activation of tetraoxane 26 with FeBr2 
7.7  Compound 27  (E)-3-styryl-6-(4-trifluoromethoxy)phenyl)-
1,2,4,5-tetraoxane 
Figure 7.37  Trifluoromethoxybenzaldehyde-tetraoxane 27 1H NMR spectra (CDCl3) 
t=0h t=0.5h 
t=1h
t=1.5h
t=2h 
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Figure 7.38  Trifluoromethoxybenzaldehyde-tetraoxane 27 COSY NMR spectra (CDCl3) 
Figure 7.39  Trifluoromethoxybenzaldehyde-tetraoxane 27 13C NMR spectra (CDCl3) 
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Figure 7.40  Trifluoromethoxybenzaldehyde-tetraoxane 27 APT NMR spectra (CDCl3) 
 
 
 
Figure 7.41  Trifluoromethoxybenzaldehyde-tetraoxane 27 HMQC NMR spectra (CDCl3) 
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Figure 7.42  Activation of tetraoxane 27 with FeBr2 
 
7.8 (E)-N-methoxy-N-methyl-3-(4-(trifluoromethyl)phenyl)acrylamide  
Figure 7.43  (E)-N-methoxy-N-methyl-3-(4-(trifluoromethyl)phenyl)acrylamide 1H NMR spectra (CDCl3) 
t=0h 
t=0.5h 
t=1h 
t=1.5h t=2h 
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7.9  Compound 34  (E)-3-(4-methoxystyryl)-6-phenyl-1,2,4,5-
tetraoxane 
  
Figure 7.44  (E)-3-(4-methoxystyryl)-6-phenyl-1,2,4,5-tetraoxane 34 1H NMR spectra (CDCl3) 
7.10 Compound 38  (1r, 3r, 5r, 7r)- -((E)-styryl)spiro[adamantane-
-[1,2,4,5]tetraoxane] 
Figure 7.45 - (1r, 3r, 5r, 7r)- -((E)-styryl)spiro[adamantane- -[1,2,4,5]tetraoxane] 38 1H NMR spectra (CDCl3) 
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7.11 Compound 39 3-((1r, 3r, 5r, 7r)-adamantan-2-yl)-6-((E)-styryl)-
1,2,4,5-tetraoxane 
Figure 7.46 - 3-((1r, 3r, 5r, 7r)-adamantan-2-yl)-6-((E)-styryl)-1,2,4,5-tetraoxane 39 1H NMR spectra (CDCl3) 
